US11534436, Compound morphine US10836728, Compound Morphine (+)-Morphine US10752592, Compound morphine BDBM224017
Morphine 6-Glucuronide(Minor) Morphine-6G MORPHINE-6-GLUCURONIDE BDBM50370478
BDBM224029 Morphine-3G Morphine-3-glucuronide
US11484525, Compound Morphine BDBM579485
US8962646, A US10512644, Compound Morphine BDBM148977
US9133125, Table D, morphine BDBM179907
BDBM208982 US9233167, a-6-mPEG1-O-Morphine
BDBM208983 US9233167, a-6-mPEG2-O-Morphine
BDBM208985 US9233167, a-6-mPEG4-O-Morphine
BDBM208986 US9233167, a-6-mPEG5-O-Morphine
BDBM208987 US9233167, a-6-mPEG6-O-Morphine
BDBM208988 US9233167, a-6-mPEG7-O-Morphine
NSC_5980 BDBM86258 Morphine CAS_23552-18-3
US9233167, a-6-mPEG3-O-Morphine BDBM208984
US9233167, a-6-mPEG9-O-Morphine BDBM208989
BDBM425895 US10512644, Compound alpha-6-mPEG1-O-Morphine
BDBM425896 US10512644, Compound alpha-6-mPEG2-O-Morphine
BDBM425898 US10512644, Compound alpha-6-mPEG4-O-Morphine
BDBM425899 US10512644, Compound alpha-6-mPEG5-O-Morphine
BDBM425900 US10512644, Compound alpha-6-mPEG6-O-Morphine
US10512644, Compound alpha-6-mPEG3-O-Morphine BDBM425897
US10512644, Compound alpha-6-mPEG7-O-Morphine BDBM425901
US10512644, Compound alpha-6-mPEG9-O-Morphine BDBM425902
4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diolMorphine 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine sulfate) (Morphine) 2-{4-[2,4-diamino-6-pteridinylmethyl(methyl)amino]phenylcarboxamido}pentanedioic acid(morphine) AVINZA 2-[2-{2-[2-(2-Amino-3-phenyl-propionylamino)-acetylamino]-acetylamino}-3-(4-hydroxy-phenyl)-propionylamino]-4-methylsulfanyl-butyric acid 3-(4-Hydroxy-phenyl)-1-propyl-piperidine-3-carboxylic acid ethyl ester (morphine) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol AMBENYL 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine)(HCl) 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(Morphine) 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol DEPODUR DIMETANE-DC (Morphine)4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (-)-morphine (1S,5R,13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (-)-(etorphine) 7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol(morphine) BROMANYL 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol,sulfate(Morphinesulfate) Morphine;4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol 1N-[2-(5-dimethylaminomethyl-2-furylmethylsulfanyl)ethyl]-1N-methyl-2-nitro-(Z)-1-ethene-1,1-diamine 6,11-Dimethyl-3-(3-methyl-but-2-enyl)-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocin-8-ol(Morphine) 4-methyl-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol (morphine) MORPHINE Analog of 14-(Arylhydroxyamino)codeinone CODRIX KADIAN 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ;sulphate salt(morphine) TRIACIN-C US9133125, Table D, morphine 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol INFUMORPH 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol((Morphine)) 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol ; HydroChloride MYBANIL CHEMBL70 4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol(morphine) BDBM50000092 BDB50000092 6-tert-Butyl-3-methyl-1,2,3,4,5,6-hexahydro-2,6-methano-benzo[d]azocine
(4R,4aR,7S,7aR,12bS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol US9233167, Morphine BDBM208981
Morphine 6-glucuronide BDBM50125682 CHEMBL19905 3,4,5-trihydroxy-6-[10-hydroxy-4-methyl-(5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraen-14-yloxy]tetrahydro-2H-2-pyrancarboxylic acid
(naloxone) 4-allyl-10,17-dihydroxy-(1S,5R,13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one 4-allyl-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one NARCAN Analog of 14-(Arylhydroxyamino)codeinone NALOXONE SUBOXONE (naloxone)4-allyl-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one BDBM50000788 (morphine)4-methyl-(1S,5R,13R,14S,17R)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol [17-(2,3-3H-2-propenyl)]-4, 5a -epoxy-3,14-dihydroxymorphinan-6-one (naloxone)4-allyl-10,17-dihydroxy-(1S,5R,13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one 4-allyl-10,17-dihydroxy-(1S,5R,13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one( Naloxone) 4-allyl-10,17-dihydroxy-(1S,5R,13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one 4-allyl-10,17-dihydroxy-(1S,5R,13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one(Naxolone) 4-allyl-10,17-dihydroxy-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one(naloxone)C2H2O4 4-allyl-10,17-dihydroxy-(1S,5R,13R,17S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10-trien-14-one (naloxone)
- Balboni, G; Salvadori, S; Marczak, ED; Knapp, BI; Bidlack, JM; Lazarus, LH; Peng, X; Si, YG; Neumeyer, JL Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic. Eur J Med Chem 46: 799-803 (2011)
- Mohacsi, E; Leimgruber, W; Baruth, H Synthesis and pharmacology of metabolically stable tert-butyl ethers of morphine and levorphanol. J Med Chem 25: 1264-6 (1982)
- Archer, S; Seyed-Mozaffari, A; Osei-Gyimah, P; Bidlack, JM; Abood, LG 14 beta-(2-bromoacetamido)morphine and 14 beta-(2-bromoacetamido)morphinone. J Med Chem 26: 1775-7 (1983)
- Wentland, MP; Lou, R; Dehnhardt, CM; Duan, W; Cohen, DJ; Bidlack, JM 3-Carboxamido analogues of morphine and naltrexone. synthesis and opioid receptor binding properties. Bioorg Med Chem Lett 11: 1717-21 (2001)
- Li, W; Tao, YM; Tang, Y; Xu, XJ; Chen, J; Fu, W; Wang, XH; Chao, B; Sheng, W; Xie, Q; Qiu, ZB; Liu, JG Highly selective and potent mu opioid ligands by unexpected substituent on morphine skeleton. Bioorg Med Chem Lett 20: 418-21 (2010)
- Gilbert, AK; Hosztafi, S; Mahurter, L; Pasternak, GW Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol 492: 123-30 (2004)
- Norwood, VM; Brice-Tutt, AC; Eans, SO; Stacy, HM; Shi, G; Ratnayake, R; Rocca, JR; Abboud, KA; Li, C; Luesch, H; McLaughlin, JP; Huigens, RW Preventing Morphine-Seeking Behavior through the Re-Engineering of Vincamine's Biological Activity. J Med Chem 63: 5119-5138 (2020)
- MacDougall, JM; Zhang, XD; Polgar, WE; Khroyan, TV; Toll, L; Cashman, JR Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett 15: 1583-6 (2005)
- Wandel, C; Kim, R; Wood, M; Wood, A Interaction of morphine, fentanyl, sufentanil, alfentanil, and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96: 913-20 (2002)
- Del Bello, F; Mattioli, L; Ghelfi, F; Giannella, M; Piergentili, A; Quaglia, W; Cardinaletti, C; Perfumi, M; Thomas, RJ; Zanelli, U; Marchioro, C; Dal Cin, M; Pigini, M Fruitful adrenergica(2C)-agonism/a(2A)-antagonism combination to prevent and contrast morphine tolerance and dependence. J Med Chem 53: 7825-35 (2010)
- Del Bello, F; Diamanti, E; Giannella, M; Mammoli, V; Marchioro, C; Mattioli, L; Titomanlio, F; Piergentili, A; Quaglia, W; Benedetti, G; Varrone, M; Pigini, M Low Doses of Allyphenyline and Cyclomethyline, Effective against Morphine Dependence, Elicit an Antidepressant-like Effect. ACS Med Chem Lett 3: 535-539 (2012)
- Crooks, PA; Kottayil, SG; Al-Ghananeem, AM; Byrn, SR; Butterfield, DA Opiate receptor binding properties of morphine-, dihydromorphine-, and codeine 6-O-sulfate ester congeners. Bioorg Med Chem Lett 16: 4291-5 (2006)
- Mammoli, V; Bonifazi, A; Del Bello, F; Diamanti, E; Giannella, M; Hudson, AL; Mattioli, L; Perfumi, M; Piergentili, A; Quaglia, W; Titomanlio, F; Pigini, M Favourable involvement ofa2A-adrenoreceptor antagonism in the I2-imidazoline binding sites-mediated morphine analgesia enhancement. Bioorg Med Chem 20: 2259-65 (2012)
- Cardinaletti, C; Mattioli, L; Ghelfi, F; Del Bello, F; Giannella, M; Bruzzone, A; Paris, H; Perfumi, M; Piergentili, A; Quaglia, W; Pigini, M Might adrenergic alpha2C-agonists/alpha2A-antagonists become novel therapeutic tools for pain treatment with morphine? J Med Chem 52: 7319-22 (2009)
- Cunningham, CW; Mercer, SL; Hassan, HE; Traynor, JR; Eddington, ND; Coop, A Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs. J Med Chem 51: 2316-20 (2008)
- Wentland, MP; Duan, W; Cohen, DJ; Bidlack, JM Selective protection and functionalization of morphine: synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives. J Med Chem 43: 3558-65 (2000)
- Blanchard, SG; Lee, PH; Pugh, WW; Hong, JS; Chang, KJ Characterization of the binding of a morphine (mu) receptor-specific ligand: Tyr-Pro-NMePhe-D-Pro-NH2, [3H]-PL17. Mol Pharmacol 31: 326-33 (1987)
- Olson, KM; Keresztes, A; Tashiro, JK; Daconta, LV; Hruby, VJ; Streicher, JM Synthesis and Evaluation of a Novel Bivalent Selective Antagonist for the Mu-Delta Opioid Receptor Heterodimer that Reduces Morphine Withdrawal in Mice. J Med Chem 61: 6075-6086 (2018)
- Schultz, AG; Wang, A; Alva, C; Sebastian, A; Glick, SD; Deecher, DC; Bidlack, JM Asymmetric syntheses, opioid receptor affinities, and antinociceptive effects of 8-amino-5,9-methanobenzocyclooctenes, a new class of structural analogues of the morphine alkaloids. J Med Chem 39: 1956-66 (1996)
- Nikolaev, VO; Boettcher, C; Dees, C; Bünemann, M; Lohse, MJ; Zenk, MH Live cell monitoring of mu-opioid receptor-mediated G-protein activation reveals strong biological activity of close morphine biosynthetic precursors. J Biol Chem 282: 27126-32 (2007)
- Deb, I; Paira, P; Hazra, A; Banerjee, S; Dutta, PK; Mondal, NB; Das, S Synthesis and characterizations of novel quinoline derivatives having mixed ligand activities at the kappa and mu receptors: Potential therapeutic efficacy against morphine dependence. Bioorg Med Chem 17: 5782-90 (2009)
- Schiller, PW; Fundytus, ME; Merovitz, L; Weltrowska, G; Nguyen, TM; Lemieux, C; Chung, NN; Coderre, TJ The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats. J Med Chem 42: 3520-6 (1999)
- Archer, S; Glick, SD; Maisonneuve, IM; Bidlack, JM; Xu, JY; Teitler, M; Sebastian, A; El-Hamouly, W; Hutchinson, I Suppression of morphine and cocaine self-administration in rats by a mixed mu antagonist-kappa agonist (N-CBM-TAMO) and a long-acting selective D1 antagonist (AS-300) Bioorg Med Chem Lett 6: 1139-1144 (1996)
- ChEMBL_146911 Displacement of [3H]DADLE from morphine-insensitive Opioid receptor delta 1 (presence of 50 nM morphine) of rat brain membranes
- ChEMBL_136087 Antagonist activity against mu-opioid receptor in guinea pig ileum in the presence of morphine
- ChEBML_135946 Inhibitory activity against mu-opioid receptor in guinea pig ileum longitudinal muscle using morphine
- ChEMBL_146912 Displacement of [3H]DADLE from morphine-sensitive Opioid receptor delta 1 (presence of 300 nM DELT-II) of rat brain membranes
- G protein signaling assays A standard [35S]GTPγS binding assay in membranes prepared from CHO cells expressing the human MOR was performed in a concentration response manner. All compounds were run in parallel with DAMGO and morphine.
- ChEMBL_2158163 Inhibition of MOR-mediated HIV1 BaL01 infection in GFP-tagged human OPRM1 transfected TZM-bl cells co-expressing HIV1 - LTR assessed as inhibition of viral entry in presence of morphine by measuring LTR-driven luciferase activity pretreated for 1 hr before infection measured after 2 to 3 days of infection
- cAMP inhibition assays he CisBio cAMP cell based assay kit that uses HTRF technology was utilized to assess MOR-mediated inhibition of cAMP. Assays were performed according to manufacturer's instructions, in the presence of 20 μM forskolin and 25 μM PDE-IV. All compounds were run in parallel with DAMGO and morphine.
- Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay Data Source: Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG) Source Affiliation: Sanford-Burnham Medical Research Institute Network: NIH Molecular Libraries Production Centers Network (MLPCN) Grant Number: 1 R03 MH085675-01 Assay Provider: Dr Ilya Bezprozvanny, UT Southwestern Medical Center , Dallas, TX Chronic pain (neuropathic pain, inflammatory pain, cancer pain) is a major health problem. Opiate-based drugs, such as morphine and morphine derivatives, are the primary standard of care for the treatment of chronic pain. Unfortunately, patients develop tolerance to opiates due to desensitization of the opiate receptor. Thus, alternative anti-nociceptive ("pain killing") pathways need to be explored for treatment of chronic pain. The N-type voltage-gated Ca2+ channels (CaV2.2s) in dorsal root ganglia neurons is a well validated target for chronic pain (1, 2). We previously demonstrated the interaction between CaV2.2 and the first PDZ domain of molecular
- SAR analysis of small molecule inhibitors of Mint-PDZ and N-type Ca2+ channel carboxyl-terminal peptide association using HTRF - Set 2 Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG) Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA) Network: NIH Molecular Libraries Production Centers Network (MLPCN) Grant Number: 1 R03 MH085675-01 Assay Provider: Dr Ilya Bezprozvanny, UT Southwestern Medical Center , Dallas, TX Chronic pain (neuropathic pain, inflammatory pain, cancer pain) is a major health problem. Opiate-based drugs, such as morphine and morphine derivatives, are the primary standard of care for the treatment of chronic pain. Unfortunately, patients develop tolerance to opiates due to desensitization of the opiate receptor. Thus, alternative anti-nociceptive ("pain killing") pathways need to be explored for treatment of chronic pain. The N-type voltage-gated Ca2+ channels (CaV2.2s) in dorsal root ganglia neurons is a well validated target for chronic pain (1, 2). We previously demonstrated the interaction between CaV2.2 and the first PDZ domain of molecula
- SAR analysis of small molecule inhibitors of Mint-PDZ and N-type Ca2+ channel carboxyl-terminal peptide association using HTRF Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG) Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA) Network: NIH Molecular Libraries Production Centers Network (MLPCN) Grant Number: 1 R03 MH085675-01 Assay Provider: Dr Ilya Bezprozvanny, UT Southwestern Medical Center , Dallas, TX Chronic pain (neuropathic pain, inflammatory pain, cancer pain) is a major health problem. Opiate-based drugs, such as morphine and morphine derivatives, are the primary standard of care for the treatment of chronic pain. Unfortunately, patients develop tolerance to opiates due to desensitization of the opiate receptor. Thus, alternative anti-nociceptive ("pain killing") pathways need to be explored for treatment of chronic pain. The N-type voltage-gated Ca2+ channels (CaV2.2s) in dorsal root ganglia neurons is a well validated target for chronic pain (1, 2). We previously demonstrated the interaction between CaV2.2 and the first PDZ domain of molecula
- uHTS Homogeneous Terbium Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG) Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA) Network: NIH Molecular Libraries Probe Production Centers Network (MLPCN) Grant Number: 1 R03 MH085675-01 Assay Provider: Dr Ilya Bezprozvanny, UT Southwestern Medical Center , Dallas, TX Chronic pain (neuropathic pain, inflammatory pain, cancer pain) is a major health problem. Opiate-based drugs, such as morphine and morphine derivatives, are the primary standard of care for the treatment of chronic pain. Unfortunately, patients develop tolerance to opiates due to desensitization of the opiate receptor. Thus, alternative anti-nociceptive ("pain killing") pathways need to be explored for treatment of chronic pain. The N-type voltage-gated Ca2+ channels (CaV2.2s) in dorsal root ganglia neurons is a well validated target for chronic pain (1, 2). We previously demonstrated the interaction between CaV2.2 and the first PDZ domain of mo
- Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC) Affiliation: The Scripps Research Institute, TSRI Assay Provider: Lakshmi A. Devi, Mount Sinai School of Medicine Network: Molecular Library Probe Production Centers Network (MLPCN) Grant Proposal Number: R03NS053751 Grant Proposal PI: Lakshmi A. Devi, Mount Sinai School of Medicine External Assay ID: OPRD1_AG_LUMI_1536_3XEC50 DCSRUN Name: Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRD1 homodimerization. Description: Opiates such as morphine are the choice analgesic in the treatment of chronic pain due to their potent and rapid action. However, their long-term use is limited because of the development of tolerance and dependence, as well as respiratory suppression and constipation (1). Due to their clinical importance, various strategie
- Late-stage fluorescence-based counterscreen for antagonists of the G-protein coupled receptor 7 (GPR7) Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC) Affiliation: The Scripps Research Institute, TSRI Assay Provider: Olivier Civelli, University of California, Irvine Network: Molecular Library Probe Production Centers Network (MLPCN) Grant Proposal Number: 1-R03-DA026557-01 Grant Proposal PI: Olivier Civelli External Assay ID: MCHR1_ANT_FLUO8_384_3X%IC50 Name: Late-stage fluorescence-based counterscreen for antagonists of the G-protein coupled receptor 7 (GPR7): cell-based dose response assay to identify antagonists of the melanin-concentrating hormone receptor 1 (MCHR1). Description: Heterotrimeric G-protein coupled receptors (GPCRs) are major targets for disease therapeutics, due in part to their broad tissue distribution, structural diversity, varied modes of action, and disease-associated mutations (1-4). For example, targeting of opiod receptors by opiates such as morphine is a widespread clinical application for GPCR modulation in
- Fluorescence-based dose response cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC) Affiliation: The Scripps Research Institute, TSRI Assay Provider: Olivier Civelli, University of California, Irvine Network: Molecular Library Probe Production Centers Network (MLPCN) Grant Proposal Number: 1-R03-DA026557-01 Grant Proposal PI: Olivier Civelli External Assay ID: GPR7_ANT_FLUO8_1536_3X%IC50 Name: Fluorescence-based dose response cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). Description: Heterotrimeric G-protein coupled receptors (GPCRs) are major targets for disease therapeutics, due in part to their broad tissue distribution, structural diversity, varied modes of action, and disease-associated mutations (1-4). For example, targeting of opiod receptors by opiates such as morphine is a widespread clinical application for GPCR modulation in pain management. The recently de-orphanized GPR7 (5) is localized predom
- Late-stage fluorescence-based dose response cell-based screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7) Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC) Affiliation: The Scripps Research Institute, TSRI Assay Provider: Olivier Civelli, University of California, Irvine Network: Molecular Library Probe Production Centers Network (MLPCN) Grant Proposal Number: 1-R03-DA026557-01 Grant Proposal PI: Olivier Civelli External Assay ID: GPR7_ANT_FLUO8_384_3X%IC50 Name: Late-stage fluorescence-based dose response cell-based screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). Description: Heterotrimeric G-protein coupled receptors (GPCRs) are major targets for disease therapeutics, due in part to their broad tissue distribution, structural diversity, varied modes of action, and disease-associated mutations (1-4). For example, targeting of opiod receptors by opiates such as morphine is a widespread clinical application for GPCR modulation in pain management. The recently de-orphanized GPR7 (5) is localized predominantl
- Late-stage fluorescence-based dose response cell-based screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7): Intracellular calcium release Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC) Affiliation: The Scripps Research Institute, TSRI Assay Provider: Olivier Civelli, University of California, Irvine Network: Molecular Library Probe Production Centers Network (MLPCN) Grant Proposal Number: 1-R03-DA026557-01 Grant Proposal PI: Olivier Civelli External Assay ID: GPR7_ANT_FLUO8_96_IC50 Name: Late-stage fluorescence-based dose response cell-based screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7): Intracellular calcium release. Description: Heterotrimeric G-protein coupled receptors (GPCRs) are major targets for disease therapeutics, due in part to their broad tissue distribution, structural diversity, varied modes of action, and disease-associated mutations (1-4). For example, targeting of opiod receptors by opiates such as morphine is a widespread clinical application for GPCR modulation in pain management. The recently de-orphanized GPR7 (5